Literature DB >> 26023805

Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.

Kristy Iglay1, Shannon E Cartier, Virginia M Rosen, Victoria Zarotsky, Swapnil N Rajpathak, Larry Radican, Kaan Tunceli.   

Abstract

OBJECTIVE: To estimate overall rates of adherence, persistence, and discontinuation for patients with type 2 diabetes mellitus (T2DM) prescribed oral antihyperglycemic agents (OAHAs) by combining results of published studies. RESEARCH DESIGN AND METHODS: A systematic literature review was conducted to identify articles published in English over the last 10 years evaluating the use of OAHAs for the treatment of T2DM. Databases searched included PubMed/MEDLINE, EMBASE, and the Cochrane Library. Seventy studies reporting adherence, persistence or discontinuation were identified by two independent reviewers and 40 reported relevant endpoints for the analysis. Outcomes included: (1) mean adherence defined as the average medication possession ratio (MPR); (2) proportion of adherent patients (MPR ≥ 80%); (3) discontinuation; and (4) persistence. Adherence and persistence were reported in observational studies only. Discontinuation was examined separately in randomized controlled trials (RCTs) and observational studies. Meta-analyses were conducted using both fixed and random effects models. When meta-analysis was not appropriate for a given outcome, descriptive statistics were provided.
RESULTS: The pooled mean MPR (95% confidence interval [CI]) was 75.3% (68.8%-81.7%; n = 13) and the proportion of adherent patients (95% CI) was 67.9% (59.6%-76.3%; n = 12). The discontinuation rate (95% CI) in RCTs was 31.8% (17.0%-46.7%; n = 7). Persistence and discontinuation were not assessed via meta-analysis for observational studies due to the limited number of available studies and differences in outcome definitions. In these studies, persistence estimates ranged from 41.0% to 81.1%, with a mean (95% CI) of 56.2% (46.1%-66.3%; n = 6), while discontinuation estimates ranged from 9.9% to 60.1%, with a mean (95% CI) of 31.4% (17.6%-45.3%; n = 6). LIMITATIONS: Limitations include (1) the use of MPR as a proxy for adherence, (2) limited number of studies available, and (3) observed heterogeneity.
CONCLUSION: The results of the analysis demonstrate that medication adherence, persistence, and discontinuation rates are suboptimal in patients with T2DM prescribed OAHAs.

Entities:  

Keywords:  Adherence; Discontinuation; Oral antihyperglycemic agents; Persistence; Type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26023805     DOI: 10.1185/03007995.2015.1053048

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  47 in total

Review 1.  The role of psychological science in efforts to improve cardiovascular medication adherence.

Authors:  Hayden B Bosworth; Dan V Blalock; Rick H Hoyle; Susan M Czajkowski; Corrine I Voils
Journal:  Am Psychol       Date:  2018-11

2.  Medication adherence: A practical measurement selection guide using case studies.

Authors:  Leah L Zullig; Phil Mendys; Hayden B Bosworth
Journal:  Patient Educ Couns       Date:  2017-02-10

3.  Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes.

Authors:  Usha Sambamoorthi; Rahul Garg; Arijita Deb; Tao Fan; Anders Boss
Journal:  Curr Med Res Opin       Date:  2017-05-19       Impact factor: 2.580

4.  Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes.

Authors:  Elena A Christofides
Journal:  Clin Diabetes       Date:  2019-07

5.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetologia       Date:  2018-12       Impact factor: 10.122

6.  Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes.

Authors:  Iakovos Avramidis; Athanasia Apsemidou; Antigoni Z Lalia; Nikolaos Petridis; Euangelos Tourtouras; Georgios Kalopitas; Georgios Pilianidis
Journal:  Clin Diabetes       Date:  2020-07

7.  Making Inroads in Addressing Population Health in Underserved Communities With Type 2 Diabetes.

Authors:  Luigi F Meneghini; Addie L Fortmann; Taylor L Clark; Kellie Rodriguez
Journal:  Diabetes Spectr       Date:  2019-11

8.  Depressive symptom dimensions and medication non-adherence in suboptimally controlled type 2 diabetes.

Authors:  Claire J Hoogendoorn; Amit Shapira; Juan F Roy; Elizabeth A Walker; Hillel W Cohen; Jeffrey S Gonzalez
Journal:  J Diabetes Complications       Date:  2018-12-07       Impact factor: 2.852

9.  The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.

Authors:  Xuejing Li; Suhui Qie; Xianying Wang; Yingying Zheng; Yang Liu; Guoqiang Liu
Journal:  Endocrine       Date:  2018-08-12       Impact factor: 3.633

10.  Associations of Chronic Medication Adherence with Emergency Room Visits and Hospitalizations.

Authors:  Michal Shani; Alex Lustman; Doron Comaneshter; Yochai Schonmann
Journal:  J Gen Intern Med       Date:  2021-05-06       Impact factor: 6.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.